




Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Required to respond to a collection of information unless it contains a valid OMB

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/703,753 |
| Filing Date | November 1, 2000 |
| First Named Inventor | Robert E. Dudley |
| Art Unit | 1617 |
| Examiner Name | S. Jiang |
| Attorney Docket Number | 01736349 |

Sheet **3** of **21****U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|-----------------|-----------------------------------|--------------------------------|--|---|
| | | Number | Kind Code ² (if known) | | | |
| S99 | 41 | US-6251436 | B1 | 06/26/2001 | Drizen, et al. | |
| | 42 | US-6266560 | B1 | 07/24/2001 | Zhang, et al. | |
| | 43 | US-6267985 | B1 | 07/31/2001 | Chen, et al. | |
| | 44 | US-6277884 | B1 | 08/21/2001 | de Tejada | |
| | 45 | US-6294192 | B1 | 09/25/2001 | Patel, et al. | |
| | 46 | US-6294550 | B1 | 09/25/2001 | Place, et al. | |
| | 47 | US-6299900 | B1 | 10/09/2001 | Reed, et al. | |
| | 48 | US-6306841 | B1 | 10/23/2001 | Place, et al. | |
| | 49 | US-6323242 | B1 | 11/27/2001 | Mueller | |
| | 50 | US-6331543 | B1 | 12/18/2001 | Garvey, et al. | |
| S99 | 51 | US-010018073 | A1 | 08/30/2001 | Dittgen, et al. | |
| | 52 | US-010023261 | A1 | 09/20/2001 | Ryoo, et al. | |
| | 53 | US-010033870 | A1 | 10/25/2001 | Luo, et al. | |
| | 54 | US-010036483 | A1 | 11/01/2001 | Luo, et al. | |
| | 55 | US-010051166 | A1 | 12/13/2001 | Luo, et al. | |
| | 56 | US-010051656 | A1 | 12/13/2001 | Place, et al. | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---------------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ | -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| S99 | 57 | WO | 92/15289 A1 | 09/17/1992 | Mantelle | | |
| | 58 | WO | 93/25168 A1 | 12/23/1993 | Heiber, et al. | | |
| | 59 | WO | 94/21230 A1 | 09/29/1994 | Elias, et al. | | |
| | 60 | WO | 94/28902 A1 | 12/22/1994 | Ellis, et al. | | |
| | 61 | WO | 96/16644 A1 | 06/06/1996 | Campbell, et al. | | |
| | 62 | WO | 96/16657 A1 | 06/06/1996 | Cambell, et al. | | |
| | 63 | WO | 96/27372 A1 | 09/12/1996 | Allen | | |
| | 64 | WO | 96/36339 A2 | 11/21/1996 | Mantzoros | | |
| | 65 | WO | 97/03985 A1 | 02/06/1997 | Daugan, et al. | | |
| | 66 | WO | 97/24148 A1 | 07/10/1997 | Chen, et al. | | |

Examiner
Signature

S99

Date
Considered

4/25/02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-01)

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



RECEIVED

PTO/SB/088B(10/01) 2002
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
TEST CENTER 1000/2000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 21

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/703,753 |
| Filing Date | November 1, 2000 |
| First Named Inventor | Robert E. Dudley |
| Group Art Unit | 1617 |
| Examiner Name | S. Jiang |
| Attorney Docket Number | 01736349 |

NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SJD | 80 | RINGHAM, ET AL., "Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel in Hypogonadal Men," Unimed Pharmaceuticals (October 31, 2000). | |
| | 81 | LONGSTRETH, ET AL., "Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment," Unimed Pharmaceuticals (October 31, 2000). | |
| | 82 | KAUFMAN, "Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation," International Journal of Impotence Research, Vol. 12 (Supplement 3), p. S75 (B9) (September 2000). | |
| | 83 | JORDAN, "Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems," American Journal of Contact Dermatitis, Vol. 8 (No. 2), pp. 108-113 (June 1997). | |
| | 84 | GOUCHIE, ET AL., "The Relationship Between Testosterone Levels and Cognitive Ability Patterns," Psychoneuroendocrinology, Vol. 16 (No. 4), pp. 323-334 (1991). | |
| | 85 | DOBS, ET AL., "Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 10), pp. 3469-3478 (1999). | |
| | 86 | PERSKY, ET AL., "Plasma Testosterone Level and Sexual Behavior of Couples," Archives of Sexual Behavior, Vol. 7 (No. 3), pp. 157-173 (May 1978). | |
| | 87 | AHMED, ET AL., "Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism," Journal Of Clinical Endocrinology And Metabolism, Vol. 66 (No. 3), pp. 546-551 (March 1988). | |
| | 88 | BALS-PRATSCH, ET AL., "Transdermal Testosterone Substitution Therapy for Male Hypogonadism," The Lancet, Vol. 2 (No. 8513), pp. 943-46 (October 25, 1986). | |
| | 89 | PLYMATE, ET AL., "Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men," Journal of Andrology, Vol. 10 (No. 5), pp. 366-371 (September-October 1989). | |
| SJD | 90 | CUNNINGHAM, ET AL., "Testosterone Replacement with Transdermal Therapeutic Systems - Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels," JAMA, Vol. 261 (No. 17), pp. 2525-2530 (May 5, 1989). | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 21

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/703,753 |
| Filing Date | November 1, 2000 |
| First Named Inventor | Robert E. Dudley |
| Group Art Unit | 1617 |
| Examiner Name | S. Jiang |
| Attorney Docket Number | 01736349 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SJD | 91 | TENOVER, ET AL., "Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men," Journal of Gerontology, Vol. 43 (No. 6), pp. M163-169 (November 1988). | |
| | 92 | CONWAY, ET AL., "Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men," International Journal Of Andrology, Vol. 11 (No. 4), pp. 247-264 (August 1988). | |
| | 93 | PLACE, ET AL., "Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone," Annals New York Academy of Sciences, Vol. 618, pp. 441-449 (1991). | |
| | 94 | BHASIN, ET AL., "A Biodegradable Testosterone Microcapsule Formulation Provides Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 1), pp. 75-83 (January 1992). | |
| | 95 | ARVER, ET AL., "Improvement of Sexual Function in Testosterone Deficient Men Treated for 1 Year with a Permeation Enhanced Testosterone Transdermal System," Journal Of Urology, Vol. 155 (No. 5), pp. 1604-1608 (May 1996). | |
| | 96 | LIAO, "Androgen Action: Molecular Mechanism and Medical Application," J. Formos Med. Assoc., Vol. 93 (No. 9), pp. 741-751 (September 1994). | |
| | 97 | CARLSTROM, ET AL., "Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function," International Journal Of Andrology (Vol. 13), pp. 67-73 (1990). | |
| | 98 | de LIGNIERES, ET AL., "Treatment of Male Hypogonadism by Topical Administration of Androgens," pp. 273-283 (1980). | |
| | 99 | DAVIDSON, ET AL., "Hormonal Changes and Sexual Function in Aging Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 57 (No. 1), pp. 71-77 (1983). | |
| | 100 | VERMEULEN, ET AL., "Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins," Maturitas, Vol. 7, pp. 281-287 (1985). | |
| SJD | 101 | MORRISON, "Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women," Psychopharmacology Bulletin, Vol. 33 (No. 2), pp. 293-296 (1997). | |

Examiner Signature

SJD

Date


Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SAJ | 102 | JAFFE, ET AL., "Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men", Horm. Res., Vol. 41, pp. 215-217 (1994). | |
| | 103 | MORLEY, ET AL., "Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy," J. Lab. Clin. Med., Vol. 135 (No. 5), pp. 370-378 (May 2000). | |
| | 104 | MARIN, ET AL., "Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues," European Journal of Medicine, Vol. 1 (No. 6), pp. 329-336 (October 1992). | |
| | 105 | WANG, ET AL., "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study," The Journal Of Endocrinology And Metabolism, Vol. 85 (No. 3), pp. 964-969 (March 2000). | |
| | 106 | KUHN, ET AL., "Percutaneous Androgen Treatment for Male Hypogonadism. Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations," Endocrinologie, Vol. 14 (No. 11), pp. 1031-1036 (1986) (English Translation). | |
| | 107 | HANDELSMAN, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Pellets in Man," Journal Of Clinical Endocrinology And Metabolism, Vol. 70 (No. 1), pp. 216-222 (1990). | |
| | 108 | STUENKEL, ET AL., "Sublingual Administration of Testosterone-Hydroxypropyl-b-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 72 (No.5), pp. 1054-1059 (May 1991). | |
| | 109 | BHASIN, "Clinical Review 34 - Androgen Treatment of Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 6), pp. 1221-1225 (June 1992). | |
| | 110 | SALEHIAN, ET AL., "Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 80 (No. 12), pp. 3567-3575 (1995). | |
| | 111 | MEIKLE, ET AL., "Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 5), pp. 1832-1840 (May 1996). | |
| SAJ | 112 | WANG, ET AL., "Testosterone Replacement Therapy Improves Mood in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3578-3583 (1996). | |

Examiner
Signature

SAJ

Date


Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|---|---|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703.753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736349 |
| Sheet | 9 | of | 21 |


| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| SJG | 113 | WANG, ET AL., "Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3654-3662 (1996). | |
| | 114 | McCLELLAN, ET AL., "Transdermal Testosterone," Drugs, Vol. 55 (No. 2), pp. 253-258 (February 1998). | |
| | 115 | BHASIN, ET AL., "Therapeutic Perspective - Issues in Testosterone Replacement in Older Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 10), pp. 3435-3448 (1998). | |
| | 116 | BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140. pp. 414-419 (1999). | |
| | 117 | BEHRE, ET AL., "Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years," Clinical Endocrinology, Vol. 50, pp. 629-635 (1999). | |
| | 118 | PARKER, ET AL., "Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1999). | |
| | 119 | SNYDER, ET AL., "Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol.84 (No. 6), pp. 1966-1972 (1999). | |
| | 120 | WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 8), pp. 2749-2757 (August 1998). | |
| | 121 | LEIFKE, ET AL., "Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men," European Journal of Endocrinology, Vol. 138. pp. 51-58 (1998). | |
| SJG | 122 | BEHRE, ET AL., "Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 82 (No. 8), pp. 2386-2390 (1997). | |
| | | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 4/25/02 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SPJ | 123 | DAMASSA, ET AL., "Sex Hormone-Binding Globulin and Male Sexual Development," Neuroscience And Biobehavioral Reviews, Vol. 19 (No. 2), pp. 165-175 (1995). | |
| | 124 | MORLEY, ET AL., "Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men," Metabolism, Vol. 46 (No. 4), pp. 410-413 (April 1997). | |
| | 125 | CUNNINGHAM, ET AL., "Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status," Journal Of Clinical Endocrinology And Metabolism, Vol. 58 (No. 5), pp. 915-918 (1984). | |
| | 126 | LEWIS, ET AL., "Serum 5a-Dihydrotestosterone and Testosterone Changes with Age in Man," ACTA Endocrinologica, Vol. 82, pp. 444-448 (1976). | |
| | 127 | HARDY, ET AL., "Endocrine Assessment of Impotence - Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin," Postgrad Medical Journal, Vol. 70, pp. 836-837 (1994). | |
| | 128 | DAVIDSON, ET AL., "Hormonal Replacement and Sexuality in Men," Clinics In Endocrinology And Metabolism, Vol. 11 (No. 3), pp. 599-623 (November 1982). | |
| | 129 | MANTZOROS, ET AL., "Contribution of Dihydrotestosterone to Male Sexual Behavior," British Medical Journal, Vol. 310, pp 1289-1291 (May 20, 1995). | |
| | 130 | MOORADIAN, ET AL., "Biological Actions of Androgens," Endocrine Reviews, Vol. 8 (No. 1), pp 1-28 (1987). | |
| | 131 | CUNNINGHAM, ET AL., "Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men," Journal Of Clinical Endocrinology and Metabolism, Vol. 70 (No. 3), pp. 792-797 (1990). | |
| | 132 | SKAKKEBAEK, ET AL., "Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study," Clinical Endocrinology, Vol. 14, pp. 49-61 (1981). | |
| SPJ | 133 | de LIGNIERES, "Transdermal Dihydrotestosterone Treatment of Andropause," Annals Of Medicine, Vol. 25, pp. 235-241 (1993). | |


Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| SJ | 134 | CHEMANA, ET AL., "Percutaneous Absorption of 5a-dihydrotestosterone in Man II. Percutaneous Administration of 5a-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis: Clinical, Metabolic and Hormonal Effectiveness," International Journal Of Andrology, Vol. 5, pp. 595-606 (1982). | |
| | 135 | McCLURE, ET AL., "Hypogonadal Impotence Treated by Transdermal Testosterone," Urology, Vol. XXXVII (No. 3), pp. 224-228 (March 1991). | |
| | 136 | GOOREN, "Androgen Levels and Sex Functions in Testosterone-Treated Hypogonadal Men," Archives Of Sexual Behavior, Vol. 16 (No. 6), pp. 463-473 (1987). | |
| | 137 | TSITOURAS, "Effects of Age on Testicular Function," Endocrinology And Metabolism Clinics, Vol. 16 (No. 4), pp.1045-1059 (December 1987). | |
| | 138 | ANDERSON, ET AL., "The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 75 (No. 6), pp.1503-1507 (1992). | |
| | 139 | KNUSSMANN, ET AL., "Relations Between Sex Hormone Levels and Sexual Behavior in Men," Archives Of Sexual Behavior, Vol. 15 (No.5), pp. 429-5 (1986). | |
| | 140 | BANCROFT, "Endocrinology of Sexual Function," Clinics In Obstetrics And Gynecology, Vol. 7 (No. 2), pp. 253-281 (August 1980). | |
| | 141 | BAGATELL, ET AL., "Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 78 (No. 3), pp. 711-716 (1994). | |
| | 142 | WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihydrotestosterone Enanthate in Non-Human Primates," ACTA Endocrinologica (COPENH), Vol. 122 (No. 4), pp. 432-442 (1990). | |
| | 143 | "Sexual Dysfunction in the Male - Sexual Arousal Disorder," The Merck Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992). | |
| SJ | 144 | JOCKENHOVEL, ET AL., "Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men," Clinical Endocrinology, Vol. 45, pp. 61-71 (1996). | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/08B (10-01)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SAJ | 145 | BEHRE, ET AL., "Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester," Journal Of Endocrinology And Metabolism," Vol. 75 (No. 5), pp. 1204-1210 (1992). | |
| | 146 | SCHURMEYER, ET AL., "Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men," International Journal of Andrology, Vol. 7, pp. 181-187 (1984). | |
| | 147 | MAZER, ET AL., "Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men," Journal of Controlled Release, Vol. 19, pp. 347-361 (1992). | |
| | 148 | COFRANCESCO, Jr., ET AL., "Transdermal Testosterone Delivery Systems," The Endocrinologist, Vol. 6 (No. 3), pp. 207-213 (1996). | |
| | 149 | BROCKS, ET AL., "Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose," Journal of Clinical Pharmacology, Vol. 36, pp. 732-739 (1996). | |
| | 150 | ARVER, ET AL., "Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men," Clinical Endocrinology, Vol. 47, pp. 727-737 (1997). | |
| | 151 | MEIKLE, ET AL., "Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.). | |
| | 152 | BALS-PRATSCH, ET AL., "Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year," ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988). | |
| | 153 | CAREY, ET AL., "Transdermal Testosterone Treatment of Hypogonadal Men," The Journal of Urology, Vol. 140, pp. 76-79, (July 1988). | |
| | 154 | CUNNINGHAM, ET AL., "Testosterone Transdermal Delivery System," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc). | |
| | 155 | Product Information - Testoderm-TTS, Physicians' Desk Reference, Alza pp. 517-520. | |


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. PATENT & TRADEMARK OFFICE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 21

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/703,753 |
| Filing Date | November 1, 2000 |
| First Named Inventor | Robert E. Dudley |
| Group Art Unit | 1617 |
| Examiner Name | S. Jiang |
| Attorney Docket Number | 01736349 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| 590 | 156 | YU, ET AL., "Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men," Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997). | |
| | 157 | YU, ET AL., "Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application," Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997). | |
| | 158 | WALTERS, "Penetration Enhancers and Their Use in Transdermal Therapeutic Systems," pp. 202-227 (1990). | |
| | 159 | GENNARO, "Remington: The Science and Practice of Pharmacy, 20th Edition," Chapter 44, pp. 842-843 (2000). | |
| | 160 | JARKANDER-ROLFF, ET AL., "Transdermal Application of A Testosterone Gel - A Pharmacokinetic Study." | |
| | 161 | TIRASSA, ET AL., "High-Dose Anabolic Androgenic Steroids Modulate Concentrations of Nerve Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain," Journal of Neuroscience Research, Vol. 47 (No. 2), pp. 198-207 (January 15, 1997). | |
| | 162 | VELDHUIS, ET AL., "Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No. 2), pp. 529-535. (2001) | |
| | 163 | MILLER, ET AL., "Androgen Deficiency in Women with Hypopituitarism," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No.2), pp. 561-567 (2001). | |
| | 164 | KAO, ET AL., "Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture," Journal of Pharmacology and Experimental Therapeutics, Vol. 241 (No. 2), pp. 482-487 (May 1987). | |
| | 165 | FINDLAY, ET AL., "Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 68 (No. 2), pp. 369-373 (February 1989). | |
| 390 | 166 | ERNESTI, ET AL., "Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture," Skin Pharmacology, Vol. 5 (No. 3), pp. 146-153 (1992). | |

Examiner
Signature

Date


Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SP | 167 | CHOI, ET AL., "Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus," Journal Of Urology, Vol. 150 (No. 2) (Part 2), pp. 657-660 (August 1993). | |
| | 168 | Testosterone, Chapters 1, 6-16 (1999). | |
| | 169 | TSAI, ET AL., "Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors." Journal of Pharmaceutical Sciences, Vol. 85 (No. 6), pp. 643-648 (June 1996). | |
| | 170 | MEIKLE, ET AL., "Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradiol and Sex-Hormone-Binding Globulin." Metabolism. Vol. 31 (No. 1), pp. 6-9 (January 1982). | |
| | 171 | SHANBHAG, ET AL., "The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone, Testosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma," J. Steroid Biochem., Vol. 24 (No. 2), pp. 549-555 (February 1986). | |
| | 172 | BELGOROSKY, ET AL., "Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys," J. Steroid Biochem., Vol. 27 (Nos. 1-3), pp. 291-295 (1987). | |
| | 173 | KORENMAN, ET AL., "Androgen Therapy of Hypogonadal Men with Transscrotal Testosterone Systems," American Journal Of Medicine, Vol. 83 (No. 3), pp. 471-478 (September 1987). | |
| | 174 | MITCHELL, ET AL., "Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive," Clinical Endocrinology (OXF), Vol. 42 (No. 5), pp. 501-507 (May 1995). | |
| | 175 | NANKIN, ET AL., "Decreased Bioavailable Testosterone In Aging Normal and Impotent Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 6), pp. 1418-1420 (December 1986). | |
| | 176 | TENOVER, ET AL., "The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate," Journal Of Clinical Endocrinology And Metabolism, Vol. 65 (No. 6), pp. 1118-1126 (December 1987). | |
| SP | 177 | WINTERS, ET AL., "The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men," Metabolism, Vol. 33 (No. 11), pp. 1052-1059 (November 1984). | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 28 2002

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 21

Complete If Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SAG | 178 | MEIKLE, ET AL., "Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 3), pp. 623-628 (March 1992). | |
| | 179 | WINTERS, ET AL., "Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. The Testoderm Study Group," Clinical Endocrinology (OXF), Vol. 47 (No. 3), pp. 317-322 (September 1997). | |
| | 180 | BOYLE, ET AL., "Serum Testosterone Measurements," American Journal Of Clinical Pathology, Vol. 81 (No. 6), pp. 754-761 (June 1984). | |
| | 181 | HOLOWNIA, ET AL., "A Clinical Evaluation of A Direct Radioimmunoassay of Testosterone," Clinical Chimica Acta, Vol. 214 (No. 1), pp. 31-43 (January 31, 1993). | |
| | 182 | BELGOROSKY, ET AL., "Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Puberty in Boys," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 2), pp. 510-512 (August 1986). | |
| | 183 | VALERO-POLITI, ET AL., "Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men," Eur. J. Clin. Chem. Clin. Biochem., Vol. 34 (No. 6), pp. 455-462 (June 1996). | |
| | 184 | VALERO-POLITI, ET AL., "Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men," Clinica Chimica Acta, Vol. 271 (No. 1), pp. 57-71 (March 9, 1998). | |
| | 185 | LONGCOPE, ET AL., "Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 71 (No. 6), pp. 1442-1446 (December 1990). | |
| | 186 | BELGOROSKY, ET AL., "Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones," J. Steroid Biochem., Vol. 18 (No. 6), pp. 783-787 (June 1983). | |
| | 187 | LEWIS, ET AL., "Proceedings: Age-Related Changes in Serum Sapha-dihydrotestosterone and Testosterone in Normal Men," Journal Of Endocrinology, Vol. 67 (No. 2), pp. 15P (November 1975). | |
| SAG | 188 | PIRKE, ET AL., "Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males," ACTA Endocrinologica (COPENH), Vol. 74 (No. 4), pp. 792-800 (December 1973). | |

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0034
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 16 of 21

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/703,753 |
| Filing Date | November 1, 2000 |
| First Named Inventor | Robert E. Dudley |
| Group Art Unit | 1617 |
| Examiner Name | S. Jiang |
| Attorney Docket Number | 01736349 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SJG | 189 | MASTERS, ET AL., "Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol," Clinical Chemistry, Vol. 35 (No. 6), pp. 979-984 (June 1989). | |
| | 190 | WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 53 (No. 5), pp. 1021-1024 (November 1981). | |
| | 191 | ZMUDA, ET AL., "Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men," Metabolism, Vol. 45 (No. 8), pp. 935-939 (August 1996). | |
| | 192 | GAIDANO, ET AL., "Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty," Clinical Chimica Acta, Vol. 100 (No. 2), pp. 91-97 (January 15, 1980). | |
| | 193 | Definition of Isopropyl Myristate (5103), The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition, p. 821 (1989). | |
| | 194 | GENNARO, ET AL., Remington's Pharmaceutical Sciences, Eighteenth Edition, pp. 1305, 1314-1315 (1990). | |
| | 195 | LANGTRY, ET AL., "Sildenafil - A Review of its Use in Erectile Dysfunction," Drugs, Vol. 57 (No. 6), pp. 967-989 (1999). | |
| | 196 | MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998). | |
| | 197 | FAHRNER, ET AL., "Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)," International Journal Of Sports Medicine, Vol. 19 (No. 1), pp. 12-15 (January 1998). [Abstract] | |
| | 198 | BARTSCH, "Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-Dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men," Maturitas, Vol. 2 (No. 2), pp. 109-118 (July 1980). [Abstract] | |
| SJG | 199 | WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," Clinical Endocrinology, Vol. 54, pp. 1-13 (2001). | |

Examiner
Signature

Date


Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 17 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| SAJ | 200 | GOOREN, "A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate," J. Androl., Vol. 15 (No. 3), pp. 212-215 (May-June 1994). [Abstract] | |
| | 201 | MAZER, "New Clinical Applications of Transdermal Testosterone Delivery in Men and Women," J. Controlled Release, Vol. 65 (No. 1-2), pp. 303-315 (March 1, 2000). [Abstract] | |
| | 202 | ITOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level," Nippon Naibunpi Gakkai Zasshi, Vol. 67 (No. 1), pp. 23-32 (January 20, 1991). [Abstract] | |
| | 203 | Male Hormone Patch Approved, Nupharm, http://www.nupharm.com/malehorm.htm . | |
| | 204 | "SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available," International Association of Physicians in AIDS Care, http://www.iapac.org/clinmgt/compnews/sb061297.html (June 12, 1997). | |
| | 205 | "Impotence Treatments," Impotence World Association, http://www.impotenceworld.org/treatment.htm (2000). | |
| | 206 | "Andro Gel," Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998). | |
| | 207 | "Cellegy Pharmaceuticals Market Opportunities," CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html (1997). | |
| | 208 | "Prospectus - Cellegy Pharmaceuticals, Inc.," OPPENHEIMER & CO., pp. 1-4, 21-28 (1997). | |
| | 209 | The Testosterone Source, http://www.testosteronesource.com (1998). | |
| SAJ | 210 | BONNEY, "Hormone Replacement Therapy for Men," American Clinical Laboratory, http://iscpubs.com/pubs/acl/acl1197.html (November/December 1997). | |

Examiner Signature

SAJ


Date Considered

4/28/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|---|----|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703.753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736349 |
| Sheet | 18 | of | 21 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | 211 | Andropausal, Los Gatos Longevity Institute, http://www.antiaging.com/andropause.html (1998). | |
| | 212 | TestoCreme - A Natural Transdermal Testosterone Replacement Therapy, www.testocreme.com . | |
| SJD | 213 | WANG, ET AL., "Pharmacokinetics Of Transdermal Testosterone Gel in Hypogonadal Men," ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM. | |
| | 214 | SWERDLOFF, ETAL., "Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men," 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000). | |
| | 215 | WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000). | |
| | 216 | WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000). | |
| | 217 | "Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.FNGHD.com (August 19, 1998). | |
| SJD | 218 | RIGGS, "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel," Unimed News Release, pp. 1-2 (March 31, 1997). | |
| | 219 | Androgel-1% (testosterone gel) CIII.; www.Androgel.com , pp. 1-2. | |
| SJD | 220 | VERGEL, "Anabolic Steroids: A Practical Guide," CRIA Update, Vol. 7 (No. 3) (Summer 1998). | |
| | 221 | MOONEY, "Frequency of Administration - Testosterone & Nandrolone," Vol. 1 (No. 4); www.medibolitics.com (Downloaded-10/8/98). | |


| | | | |
|--------------------|------------|-----------------|---------|
| Examiner Signature | <i>SJD</i> | Date Considered | 4/25/02 |
|--------------------|------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 19 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SD | 222 | Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (December 1997). | |
| SD | 223 | "Anabolic Steroid Boosts Weight," GMHC Treatment Issues, Vol. 10, No. 9 (September 1996). | |
| | 224 | Anabolic Steroids, Project Inform Hotline Handout, www.projinf.org. (Downloaded-10/8/98). | |
| | 225 | Anabolic Steroids - A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded 10/27/98). | |
| | 226 | USP Drug Information - Anabolic Steroids (Systemic), MayoClinic, www.mayohealth.org (Downloaded-10/8/98). | |
| SD | 227 | MOONEY, "Anabolic Steroids For AIDS Therapy: Differences Between Analogs," No. 1, www.digiweb.com. (July 1998). | |
| | 228 | Testocrema - No Shots, No Pills, No Patches, www.testocrema.com (Downloaded-7/10/00). | |
| SD | 229 | "ENDO 99: Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women," www.pslgroup.com (June 15, 1999). | |
| SD | 230 | "Data Supports Safety of Estratest For Men," Doctor's Guide, www.pslgroup.com (March 9, 1998). | |
| SD | 231 | "Testosterone's Role in the Female Sex Drive," USA Today News, www.usatoday.com (April 8, 1996). | |
| | 232 | "Alternative to Viagra For Women?," www.mdhealthline.com (Downloaded-8/7/00). | |

Examiner
Signature

SD

Date
Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|----|----|----|
| Sheet | 20 | of | 21 |
|-------|----|----|----|

| Complete If Known | |
|------------------------|------------------|
| Application Number | 09/703,753 |
| Filing Date | November 1, 2000 |
| First Named Inventor | Robert E. Dudley |
| Group Art Unit | 1617 |
| Examiner Name | S. Jiang |
| Attorney Docket Number | 01736349 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| SSD | 233 | "Never Too Buff," Time Europe, www.time.com, Vol. 155 (No. 16) (April 24, 2000). | |
| | 234 | Gefael, Graeme's Testosterone Page, www.voyager.co.nz (5/12/00). | |
| | 235 | Estrogel, www.netdoktor.dk/medicin/Fakta/Estrogel (Downloaded 6/26/01). | |
| | 236 | La Sexualite . . . , L'Androgel, Le Gel Miracle, www.aci-multimedia.net/feminin/androgel (Downloaded 5/9/01). | |
| | 237 | Stehli, et al., Info . . . , Info . . . , Info . . . - Androgel, www.mageos:ifrance.com/nade38/androgel (Downloaded 5/9/01). | |
| | 238 | CHERRIER, ET AL., "T-Gel Study: Cognitive Effects of Exogenous Testosterone Manipulation in Hypogonadal Men" (6/7/99). | |
| | 239 | "Bentley Pharmaceuticals Annouces Research and Licensing Agreements For Intranasal Pain Management and Topical Hormone Replacement Therapy," www.bentleypharm.com (downloaded 11/17/01). | |
| | 240 | "Testosterone Gel May Help Men with Low Sex Drive," WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/08-14-tgel/ (August 14, 1997). | |
| | 241 | "Testocrema Transdermal Testosterone Is New," Preventive Medicine Clinic Of Monterey, http://www.wellnessmd.com/testo.html. | |
| | 242 | "SEPA Testosterone Transdermal Gel Receives Application by FDA," Doctor's Guide Global Edition, http://psigroup.com/dg/123aa.htm (January 15, 1997). | |
| | 243 | Press Release - 10/21/99 -- MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone, http://www.mchm.com/press/pr24.asp (October 21, 1999). | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 4/25/02 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 28 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 21 of 21

Complete If Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736615

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | 244 | AndrosteDERM, http://www.gethuge.net/androderm1.htm . | |
| | 245 | MANOS, "FDA Approves Gel to Treat Low Testosterone Levels," www.testocrema.com (Downloaded 5/09/01). | |
| | 246 | "Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.INCIID.com (August 19, 1998). | |
| SJO | 247 | LACAYO, "Are You Man Enough?," Time Europe, www.Time.com , Vol. 155, No. 16 (April 24, 2000). | |
| | 248 | "MacroChem Accelerates Development of Top For Impotence," www.pslgroup.com (April 10, 1997). | |
| SJO | 249 | BRADLEY, "Potential Expanded Indications for Androgen Treatment," The Endocrine Society, No. 166 (ENDO 2000). | |
| | 250 | WANG, ET AL., "New Androgen Formulations," The Endocrine Society, No. 167 (ENDO 2000). | |
| | 251 | WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," The Endocrine Society, No. 1360 (ENDO 2000). | |
| | 252 | WITTERT, ET AL., "Androgen Deficiency in Aging Men," The Endocrine Society, No. 1626 (ENDO 2000). | |
| SJO | 253 | BRILL, ET AL., "Single and Joint Impact of One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strength, Balance, Function and Muscle IGF-I and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover," The Endocrine Society, No. 1647 (ENDO 2000). | |

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/703,753 |
| | | | | Filing Date | November 1, 2000 |
| | | | | First Named Inventor | Robert E. Dudley |
| | | | | Art Unit | 1617 |
| | | | | Examiner Name | S. Jiang |
| | | | | Attorney Docket Number | 01736349 |
| Sheet | 1 | of | 21 | | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|---------------|---------------------------------|--------------------------------|--|---|
| Examiner Initials* | Cite No. 1 | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code 2 (if known) | | | |
| SP | 1 | US-4496556 | 01/29/1985 | Orentreich | |
| | 2 | US-4695465 | 09/22/1987 | Kigasawa, et al. | |
| | 3 | US-4863970 | 09/05/1989 | Patel, et al. | |
| | 4 | US-4946870 | 08/07/1990 | Partain, et al. | |
| | 5 | US-5053227 | 10/01/1991 | Chiang, et al. | |
| | 6 | US-5059603 | 10/22/1991 | Rubin | |
| | 7 | US-5152997 | 10/06/1992 | Ebert, et al. | |
| | 8 | US-5256652 | 10/26/1993 | El-Rashidy | |
| | 9 | US-5324521 | 06/28/1994 | Gertner, et al. | |
| | 10 | US-5332577 | 07/26/1994 | Gertner, et al. | |
| | 11 | US-5340586 | 08/23/1994 | Pike, et al. | |
| | 12 | US-5346901 | 09/13/1994 | Bell, et al. | |
| | 13 | US-5362497 | 11/08/1994 | Yamada, et al. | |
| | 14 | US-5413794 | 05/09/1995 | Suzuki, et al. | |
| | 15 | US-5460820 | 10/24/1995 | Ebert, et al. | |
| | 16 | US-5550107 | 08/27/1996 | Labrie | |
| | 17 | US-5648350 | 07/15/1997 | De Lignieres | |
| | 18 | US-5719197 | 02/17/1998 | Kanios, et al. | |
| | SP | 19 | US-5723114 | 03/03/1998 | Thornfeldt, et al. |
| 20 | | US-5744162 | 04/28/1998 | Okabe, et al. | |

[illegible]

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner Signature |  | Date Considered | 5/26/02 |
|-----------------------|---|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office: U.S. DÉPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/703,753 |
| | | | | Filing Date | November 1, 2000 |
| | | | | First Named Inventor | Robert E. Dudley |
| | | | | Art Unit | 1617 |
| | | | | Examiner Name | S. Jiang |
| Sheet | 2 | of | 21 | Attorney Docket Number | 01736349 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| SAC | 21 | US-5785991 | 07/28/1998 | Burkoth, et al. | |
| | 22 | US-5788983 | 08/04/1998 | Chien, et al. | |
| | 23 | US-5855905 | 01/05/1999 | Oettel, et al. | |
| | 24 | US-5877216 | 03/02/1999 | Place, et al. | |
| | 25 | US-5932227 | 08/03/1999 | Higo, et al. | |
| | 26 | US-5955455 | 09/21/1999 | Labrie | |
| | 27 | US-6010716 | 01/04/2000 | Saunal, et al. | |
| | 28 | US-6036977 | 03/14/2000 | Drizen, et al. | |
| | 29 | US-6037346 | 03/14/2000 | Doherty, et al. | |
| | 30 | US-6075028 | 06/13/2000 | Graham | |
| | 31 | US-6077841 | 06/20/2000 | Sui, et al. | |
| | 32 | US-6087362 | 07/11/2000 | El-Rashidy | |
| | 33 | US-6087368 | 07/11/2000 | Macor, et al. | |
| | 34 | US-6103765 | 08/15/2000 | Neal | |
| | 35 | US-6124461 | 09/26/2000 | Shoemaker | |
| | 36 | US-6127363 | 10/03/2000 | Doherty, et al. | |
| | 37 | US-6139873 | 10/31/2000 | Hughes, Jr., et al. | |
| | 38 | US-6156753 | 12/05/2000 | Doherty, et al. | |
| | 39 | US-6238284 B1 | 05/29/2001 | Dittgen, et al. | |
| | 40 | US-6248363 B1 | 06/19/2001 | Patel, et al. | |

APR 6 2002
 TECH CENTER 1600/2900

[illegible]

| | | | |
|-----------------------|------------|--------------------|---------|
| Examiner Signature | <i>SAJ</i> | Date Considered | 5/21/02 |
|-----------------------|------------|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703.753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736349 |
| Sheet | 3 | of | 21 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| SJG | 41 | US-6251436 B1 | 06/26/2001 | Drizen, et al. | |
| | 42 | US-6266560 B1 | 07/24/2001 | Zhang, et al. | |
| | 43 | US-6267985 B1 | 07/31/2001 | Chen, et al. | |
| | 44 | US-6277884 B1 | 08/21/2001 | de Tejada | |
| | 45 | US-6294192 B1 | 09/25/2001 | Patel, et al. | |
| | 46 | US-6294550 B1 | 09/25/2001 | Place, et al. | |
| | 47 | US-6299900 B1 | 10/09/2001 | Reed, et al. | |
| | 48 | US-6306841 B1 | 10/23/2001 | Place, et al. | |
| | 49 | US-6323242 B1 | 11/27/2001 | Mueller | |
| | 50 | US-6331543 B1 | 12/18/2001 | Garvey, et al. | |
| | 51 | US-010018073 A1 | 08/30/2001 | Dittgen, et al. | |
| | 52 | US-010023261 A1 | 09/20/2001 | Ryoo, et al. | |
| | 53 | US-010033870 A1 | 10/25/2001 | Luo, et al. | |
| | 54 | US-010036483 A1 | 11/01/2001 | Luo, et al. | |
| SJG | 55 | US-010051166 A1 | 12/13/2001 | Luo, et al. | |
| | 56 | US-010051656 A1 | 12/13/2001 | Place, et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| SJG | 57 | WO 92/15289 A1 | 09/17/1992 | Mantelle | |
| | 58 | WO 93/25168 A1 | 12/23/1993 | Heiber, et al. | |
| | 59 | WO 94/21230 A1 | 09/29/1994 | Elias, et al. | |
| | 60 | WO 94/28902 A1 | 12/22/1994 | Ellis, et al. | |
| | 61 | WO 96/16644 A1 | 06/06/1996 | Campbell, et al. | |
| | 62 | WO 96/16657 A1 | 06/06/1996 | Cambell, et al. | |
| | 63 | WO 96/27372 A1 | 09/12/1996 | Allen | |
| | 64 | WO 96/36339 A2 | 11/21/1996 | Mantzoros | |
| | 65 | WO 97/03985 A1 | 02/06/1997 | Daugan, et al. | |
| SJG | 66 | WO 97/24148 A1 | 07/10/1997 | Chen, et al. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
| SJG | 5/21/02 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/703.753 |
| | | | | Filing Date | November 1, 2000 |
| | | | | First Named Inventor | Robert E. Dudley |
| | | | | Art Unit | 1617 |
| | | | | Examiner Name | S. Jiang |
| Sheet | 4 | of | 21 | Attorney Docket Number | 01736349 |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------|-------------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No.1 | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
| | | Country Code 3 | -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| SAJ | 67 | WO | 97/43989 | A1 | 11/27/1997 | Portman, et al. | |
| | 68 | WO | 98/34621 | A1 | 08/13/1998 | Rako | |
| | 69 | WO | 99/24041 | A1 | 05/20/1999 | Mak, et al. | |
| | 70 | WO | 99/66870 | A1 | 12/29/1999 | Fotinos | |
| | 71 | WO | 00/45795 | A2 | 08/10/2000 | Lulla, et al. | |
| | 72 | WO | 00/76522 | A1 | 12/21/2000 | Rosario-Jansen, et al. | |
| | 73 | WO | 01/52823 | A2 | 07/26/2001 | Kanios | |
| | 74 | WO | 01/76608 | A1 | 10/18/2001 | Lipp, et al. | |
| | 75 | EP | 0196769 | A2 | 10/08/1996 | Chien, et al. | |
| | 76 | EP | 0483105 | B2 | 04/29/1992 | Clearv | |

| | | | |
|--------------------|------------|-----------------|-----------|
| Examiner Signature | <i>SAG</i> | Date Considered | 5/21/2002 |
|--------------------|------------|-----------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/703.753 |
| | | | | Filing Date | November 1, 2000 |
| | | | | First Named Inventor | Robert E. Dudley |
| | | | | Art Unit | 1617 |
| | | | | Examiner Name | S. Jiang |
| Sheet | 5 | of | 21 | Attorney Docket Number | 01736349 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | |
| SPJ | 77 | EP 0491076 A1 | 06/24/1992 | Patel, et al. | |
| | 78 | EP 0513832 A1 | 11/19/1992 | Parab | |
| SPJ | 79 | EP 0581587 A2 | 02/02/1994 | Kobayashi, et al. | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| | | | |
|-----------------------|------------|--------------------|---------|
| Examiner Signature | <i>SPJ</i> | Date Considered | 5/26/02 |
|-----------------------|------------|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|-----------------------|
| SAG | 80 | RINGHAM, ET AL., "Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel in Hypogonadal Men," Unimed Pharmaceuticals (October 31, 2000). | TECH CENTER 1000/2900 |
| | 81 | LONGSTRETH, ET AL., "Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment," Unimed Pharmaceuticals (October 31, 2000). | TECH CENTER 1000/2900 |
| | 82 | KAUFMAN, "Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation," International Journal of Impotence Research, Vol. 12 (Supplement 3), p. S75 (B9) (September 2000). | TECH CENTER 1000/2900 |
| | 83 | JORDAN, "Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems," American Journal of Contact Dermatitis, Vol. 8 (No. 2), pp. 108-113 (June 1997). | TECH CENTER 1000/2900 |
| | 84 | GOUCHIE, ET AL., "The Relationship Between Testosterone Levels and Cognitive Ability Patterns," Psychoneuroendocrinology, Vol. 16 (No. 4), pp. 323-334 (1991). | TECH CENTER 1000/2900 |
| | 85 | DOBS, ET AL., "Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 10), pp. 3469-3478 (1999). | TECH CENTER 1000/2900 |
| | 86 | PERSKY, ET AL., "Plasma Testosterone Level and Sexual Behavior of Couples," Archives of Sexual Behavior, Vol. 7 (No. 3), pp. 157-173 (May 1978). | TECH CENTER 1000/2900 |
| | 87 | AHMED, ET AL., "Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism," Journal Of Clinical Endocrinology And Metabolism, Vol. 66 (No. 3), pp. 546-551 (March 1988). | TECH CENTER 1000/2900 |
| | 88 | BALS-PRATSCH, ET AL., "Transdermal Testosterone Substitution Therapy for Male Hypogonadism," The Lancet, Vol. 2 (No. 8513), pp. 943-46 (October 25, 1986). | TECH CENTER 1000/2900 |
| | 89 | PLYMATE, ET AL., "Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men," Journal of Andrology, Vol. 10 (No. 5), pp. 366-371 (September-October 1989). | TECH CENTER 1000/2900 |
| SAG | 90 | CUNNINGHAM, ET AL., "Testosterone Replacement with Transdermal Therapeutic Systems - Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels," JAMA, Vol. 261 (No. 17), pp. 2525-2530 (May 5, 1989). | TECH CENTER 1000/2900 |

Examiner
Signature

SAG

Date
Considered

5/24/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 16 2002
RECEIVED
APR 16 2002

| | | | |
|---|---|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703,753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736349 |
| Sheet | 7 | of | 21 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| SAG | 91 | TENOVER, ET AL., "Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men," Journal of Gerontology, Vol. 43 (No. 6), pp. M163-169 (November 1988). | |
| | 92 | CONWAY, ET AL., "Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men," International Journal Of Andrology, Vol. 11 (No. 4), pp. 247-264 (August 1988). | |
| | 93 | PLACE, ET AL., "Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone," Annals New York Academy of Sciences, Vol. 618, pp. 441-449 (1991). | |
| | 94 | BHASIN, ET AL., "A Biodegradable Testosterone Microcapsule Formulation Provides Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 1), pp. 75-83 (January 1992). | |
| | 95 | ARVER, ET AL., "Improvement of Sexual Function in Testosterone Deficient Men Treated for 1-Year with Permeation Enhanced Testosterone Transdermal System," Journal Of Urology, Vol. 155 (No. 5), pp. 1604-1608 (May 1996). | |
| | 96 | LIAO, "Androgen Action: Molecular Mechanism and Medical Application," J Formos Med. Assoc., Vol. 93 (No. 9), pp. 741-751 (September 1994). | |
| | 97 | CARLSTROM, ET AL., "Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function," International Journal Of Andrology (Vol. 13), pp. 67-73 (1990). | |
| | 98 | de LIGNIERES, ET AL., "Treatment of Male Hypogonadism by Topical Administration of Androgens," pp. 273-283 (1980). | |
| | 99 | DAVIDSON, ET AL., "Hormonal Changes and Sexual Function in Aging Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 57 (No. 1), pp. 71-77 (1983). | |
| | 100 | VERMEULEN, ET AL., "Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins," Maturitas, Vol. 7, pp. 281-287 (1985). | |
| SAG | 101 | MORRISON, "Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women," Psychopharmacology Bulletin, Vol. 33 (No. 2), pp. 293-296 (1997). | |

| | | | |
|--------------------|-----|-----------------|---------|
| Examiner Signature | SAG | Date Considered | 5/24/02 |
|--------------------|-----|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

APR 16 2002

RECEIVED

| | | | |
|---|---|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703.753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736349 |
| Sheet | 8 | of | 21 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| SAD | 102 | JAFFE, ET AL., "Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men", Horm. Res., Vol. 41, pp. 215-217 (1994). | |
| | 103 | MORLEY, ET AL., "Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy," J. Lab. Clin. Med., Vol. 135 (No. 5), pp. 370-378 (May 2000). | |
| | 104 | MARIN, ET AL., "Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues," European Journal of Medicine, Vol. 1 (No. 6), pp. 329-336 (October 1992). | |
| | 105 | WANG, ET AL., "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study," The Journal Of Endocrinology And Metabolism, Vol. 85 (No. 3), pp. 964-969 (March 2000). | |
| | 106 | KUHN, ET AL., "Percutaneous Androgen Treatment for Male Hypogonadism: Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations," Endocrinologie, Vol. 14 (No. 11), pp. 1031-1036 (1986) (English Translation). | |
| | 107 | HANDELSMAN, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Pellets in Man," Journal Of Clinical Endocrinology And Metabolism, Vol. 70 (No. 1), pp. 216-222 (1990). | |
| | 108 | STUENKEL, ET AL., "Sublingual Administration of Testosterone-Hydroxypropyl-b-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 72 (No.5), pp. 1054-1059 (May 1991). | |
| | 109 | BHASIN, "Clinical Review 34 - Androgen Treatment of Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 6), pp. 1221-1225 (June 1992). | |
| | 110 | SALEHIAN, ET AL., "Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 80 (No. 12), pp. 3567-3575 (1995). | |
| | 111 | MEIKLE, ET AL., "Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 5), pp. 1832-1840 (May 1996). | |
| SAD | 112 | WANG, ET AL., "Testosterone Replacement Therapy Improves Mood in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3578-3583 (1996). | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
| SAD | 5/24/02 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

TECH CENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| 399 | 113 | WANG, ET AL., "Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3654-3662 (1996). | |
| | 114 | McCLELLAN, ET AL., "Transdermal Testosterone," Drugs, Vol. 55 (No. 2), pp. 253-258 (February 1998). | |
| | 115 | BHASIN, ET AL., "Therapeutic Perspective - Issues in Testosterone Replacement in Older Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 10), pp. 3435-3448 (1998). | |
| | 116 | BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140, pp. 414-419 (1999). | |
| | 117 | BEHRE, ET AL., "Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years," Clinical Endocrinology, Vol. 50, pp. 629-635 (1999). | |
| | 118 | PARKER, ET AL., "Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1999). | |
| | 119 | SNYDER, ET AL., "Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 6), pp. 1966-1972 (1999). | |
| | 120 | WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 8), pp. 2749-2757 (August 1998). | |
| | 121 | LEIFKE, ET AL., "Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men," European Journal of Endocrinology, Vol. 138, pp. 51-58 (1998). | |
| 599 | 122 | BEHRE, ET AL., "Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 82 (No. 8), pp. 2386-2390 (1997). | |
| | | | |

TECH CENTER 1600/2900

TECH CENTER 1600/2900

APR 16 2002

RECEIVED

APR 16 2002

RECEIVED

Examiner Signature

509

Date Considered

5/24/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|---|----|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703,753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736349 |
| Sheet | 10 | of | 21 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| SA | 123 | DAMASSA, ET AL., "Sex Hormone-Binding Globulin and Male Sexual Development," Neuroscience And Biobehavioral Reviews, Vol. 19 (No. 2), pp. 165-175 (1995). | |
| | 124 | MORLEY, ET AL., "Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men," Metabolism, Vol. 46 (No. 4), pp. 410-413 (April 1997). | |
| | 125 | CUNNINGHAM, ET AL., "Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status," Journal Of Clinical Endocrinology And Metabolism, Vol. 58 (No. 5), pp. 915-918 (1984). | |
| | 126 | LEWIS, ET AL., "Serum 5a-Dihydrotestosterone and Testosterone Changes with Age in Man," ACTA Endocrinologica, Vol. 82, pp. 444-448 (1976). | |
| | 127 | HARDY, ET AL., "Endocrine Assessment of Impotence - Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin," Postgrad Medical Journal, Vol. 70, pp. 836-837 (1994). | |
| | 128 | DAVIDSON, ET AL., "Hormonal Replacement and Sexuality in Men," Clinics In Endocrinology And Metabolism, Vol. 11 (No. 3), pp. 599-623 (November 1982). | |
| | 129 | MANTZOROS, ET AL., "Contribution of Dihydrotestosterone to Male Sexual Behavior," British Medical Journal, Vol. 310, pp 1289-1291 (May 20, 1995). | |
| | 130 | MOORADIAN, ET AL., "Biological Actions of Androgens," Endocrine Reviews, Vol. 8 (No. 1), pp 1-28 (1987). | |
| | 131 | CUNNINGHAM, ET AL., "Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men," Journal Of Clinical Endocrinology and Metabolism, Vol. 70 (No. 3), pp. 792-797 (1990). | |
| | 132 | SKAKKEBAEK, ET AL., "Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study," Clinica Endocrinology, Vol. 14, pp. 49-61 (1981). | |
| SA | 133 | de LIGNIERES, "Transdermal Dihydrotestosterone Treatment of Andropause," Annals Of Medicine, Vol. 25, pp. 235-241 (1993). | |

| | | | |
|--------------------|-----------|-----------------|---------|
| Examiner Signature | <i>SA</i> | Date Considered | 5/24/02 |
|--------------------|-----------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 16 2002

RECEIVED
APR 16 2002

| | | | |
|---|------------------------|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703,753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| Sheet 11 of 21 | Attorney Docket Number | 01736349 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|---|--|----------------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| SAD | 134 | CHEMANA, ET AL., "Percutaneous Absorption of 5a-dihydrotestosterone in Man II. Percutaneous Administration of 5a-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis: Clinical, Metabolic and Hormonal Effectiveness," International Journal Of Andrology, Vol. 5, pp. 595-606 (1982). | TECHCENTER 1600/2900 |
| | 135 | McCLURE, ET AL., "Hypogonadal Impotence Treated by Transdermal Testosterone," Urology, Vol. XXXVII (No. 3), pp. 224-228 (March 1991). | |
| | 136 | GOOREN, "Androgen Levels and Sex Functions in Testosterone-Treated Hypogonadal Men," Archives Of Sexual Behavior, Vol. 16 (No. 6), pp. 463-473 (1987). | |
| | 137 | TSITOURAS, "Effects of Age on Testicular Function," Endocrinology And Metabolism Clinics, Vol. 16 (No. 4), pp.1045-1059 (December 1987). | |
| | 138 | ANDERSON, ET AL., "The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 75 (No. 6), pp.1503-1507 (1992). | |
| | 139 | KNUSSMANN, ET AL., "Relations Between Sex Hormone Levels and Sexual Behavior in Men," Archives Of Sexual Behavior, Vol. 15 (No.5), pp. 429-5 (1986). | |
| | 140 | BANCROFT, "Endocrinology of Sexual Function," Clinics In Obstetrics And Gynecology, Vol. 7 (No. 2), pp. 253-281 (August 1980). | |
| | 141 | BAGATELL, ET AL., "Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 78 (No. 3), pp. 711-716 (1994). | |
| | 142 | WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihydrotestosterone Enanthate in Non-Human Primates," ACTA Endocrinologica (COPENH), Vol. 122 (No. 4), pp. 432-442 (1990). | |
| | 143 | "Sexual Dysfunction in the Male - Sexual Arousal Disorder," The Merck Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992). | |
| 144 | JOCKENHOVEL, ET AL., "Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men," Clinical Endocrinology, Vol. 45, pp. 61-71 (1996). | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
| SAD | 5/24/02 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

APR 16 2002

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SAJ | 145 | BEHRE, ET AL., "Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester," Journal Of Endocrinology And Metabolism, Vol. 75 (No. 5), pp. 1204-1210 (1992). | |
| | 146 | SCHURMEYER, ET AL., "Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men," International Journal of Andrology, Vol. 7, pp. 181-187 (1984). | |
| | 147 | MAZER, ET AL., "Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men," Journal of Controlled Release, Vol. 19, pp. 347-361 (1992). | |
| | 148 | COFRANCESCO, Jr., ET AL., "Transdermal Testosterone Delivery System," The Endocrinologist, Vol. 6 (No. 3), pp. 207-213 (1996). | |
| | 149 | BROCKS, ET AL., "Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose," Journal of Clinical Pharmacology, Vol. 36, pp. 732-739 (1996). | |
| | 150 | ARVER, ET AL., "Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men," Clinical Endocrinology, Vol. 47, pp. 727-737 (1997). | |
| | 151 | MEIKLE, ET AL., "Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.). | |
| | 152 | BALS-PRATSCH, ET AL., "Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year," ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988). | |
| | 153 | CAREY, ET AL., "Transdermal Testosterone Treatment of Hypogonadal Men," The Journal of Urology, Vol. 140, pp. 76-79, (July 1988). | |
| | 154 | CUNNINGHAM, ET AL., "Testosterone Transdermal Delivery System," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc.). | |
| SAJ | 155 | Product Information - Testoderm TTS, Physicians' Desk Reference, Alza pp 517-520. | |

RECEIVED

RECEIVED

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| SAJ | 156 | YU, ET AL., "Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men," Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997). | |
| | 157 | YU, ET AL., "Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application," Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997). | |
| | 158 | WALTERS, "Penetration Enhancers and Their Use in Transdermal Therapeutic Systems," pp. 202-227 (1990). | |
| | 159 | GENNARO, "Remington: The Science and Practice of Pharmacy, 20th Edition Chapter 44, pp. 842-843 (2000). | |
| | 160 | JARKANDER-ROLFF, ET AL., "Transdermal Application of A Testosterone Gel - A Pharmacokinetic Study." | |
| | 161 | TIRASSA, ET AL., "High-Dose Anabolic Androgenic Steroids Modulate Concentrations of Ne Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain," Journal of Neuroscience Research, Vol. 47 (No. 2), pp. 198-207 (January 15, 1997). | |
| | 162 | VELDHUIS, ET AL., "Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No. 2), pp. 529-535. (2001) | |
| | 163 | MILLER, ET AL., "Androgen Deficiency in Women with Hypopituitarism," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No.2), pp. 561-567 (2001). | |
| | 164 | KAO, ET AL., "Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture," Journal of Pharmacology and Experimental Therapeutics, Vol. 241 (No. 2), pp. 482-487 (May 1987). | |
| | 165 | FINDLAY, ET AL., "Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 68 (No. 2), pp. 369-373 (February 1989). | |
| SAJ | 166 | ERNESTI, ET AL., "Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture," Skin Pharmacology, Vol. 5 (No. 3), pp. 146-153 (1992). | |

Examiner Signature

Date Considered

5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

| | | | |
|---|----|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703,753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736349 |
| Sheet | 14 | of | 21 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| SAG | 167 | CHOI, ET AL., "Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus," Journal Of Urology, Vol. 150 (No. 2) (Part 2), pp. 657-660 (August 1993). | |
| | 168 | Testosterone, Chapters 1, 6-16 (1999). | |
| | 169 | TSAI, ET AL., "Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors," Journal of Pharmaceutical Sciences, Vol. 85 (No. 6), pp. 643-648 (June 1996). | |
| | 170 | MEIKLE, ET AL., "Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradiol and Sex-Hormone-Binding Globulin," Metabolism, Vol. 31 (No. 1), pp. 6-9 (January 1982). | |
| | 171 | SHANBHAG, ET AL., "The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone, Testosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma," J. Steroid Biochem., Vol. 24 (No. 2), pp. 549-555 (February 1986). | |
| | 172 | BELGOROSKY, ET AL., "Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys," J. Steroid Biochem., Vol. 27 (Nos. 1-3), pp. 291-295 (1987). | |
| | 173 | KORENMAN, ET AL., "Androgen Therapy of Hypogonadal Men with Transscrotal Testosterone Systems," American Journal Of Medicine, Vol. 83 (No. 3), pp. 471-478 (September 1987). | |
| | 174 | MITCHELL, ET AL., "Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive," Clinical Endocrinology (OXF), Vol. 42 (No. 5), pp. 501-507 (May 1995). | |
| | 175 | NANKIN, ET AL., "Decreased Bioavailable Testosterone In Aging Normal and Impotent Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 6), pp. 1418-1420 (December 1986). | |
| | 176 | TENOVER, ET AL., "The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate," Journal Of Clinical Endocrinology And Metabolism, Vol. 65 (No. 6) pp. 1118-1126 (December 1987). | |
| SAG | 177 | WINTERS, ET AL., "The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men," Metabolism, Vol. 33 (No. 11), pp. 1052-1059 (November 1984). | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
| SAG | 5/21/02 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

APR 16 2002

TECH CENTER 1600/2900

| | | | |
|---|------------------------|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703,753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| Sheet 15 of 21 | Attorney Docket Number | 01736349 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|---------------------------|---|----------------|
| Examiner Initials* | Citation No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| SAG | 178 | MEIKLE, ET AL., "Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 3), pp. 623-628 (March 1992). | |
| | 179 | WINTERS, ET AL., "Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. The Testoderm Study Group," Clinical Endocrinology (OXF), Vol. 47 (No. 3), pp. 317-322 (September 1997). | |
| | 180 | BOYLE, ET AL., "Serum Testosterone Measurements," American Journal Of Clinical Pathology, Vol. 81 (No. 6), pp. 754-761 (June 1984). | |
| | 181 | HOLOWNIA, ET AL., "A Clinical Evaluation of A Direct Radioimmunoassay of Testosterone," Clinical Chimica Acta, Vol. 214 (No. 1), pp. 31-43 (January 31, 1993). | |
| | 182 | BELGOROSKY, ET AL., "Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Puberty in Boys," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 2), pp. 510-512 (August 1986). | |
| | 183 | VALERO-POLITI, ET AL., "Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men," Eur. J. Clin. Chem. Clin. Biochem., Vol. 34 (No. 6), pp. 455-462 (June 1996). | |
| | 184 | VALERO-POLITI, ET AL., "Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men," Clinica Chimica Acta, Vol. 271 (No. 1), pp. 57-71 (March 9, 1998). | |
| | 185 | LONGCOPE, ET AL., "Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 71 (No. 6), pp. 1442-1446 (December 1990). | |
| | 186 | BELGOROSKY, ET AL., "Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones," J. Steroid Biochem., Vol. 18 (No. 6), pp. 783-787 (1983). | |
| | 187 | LEWIS, ET AL., "Proceedings: Age-Related Changes in Serum 5alpha-dihydrotestosterone and Testosterone in Normal Men," Journal Of Endocrinology, Vol. 67 (No. 2), pg. 15P (November 1975). | |
| SAG | 188 | PIRKE, ET AL., "Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males," ACTA Endocrinologica (COPENH), Vol. 74 (No. 4), pp. 792-800 (December 1973). | |

| | | | |
|--------------------|------------|-----------------|---------|
| Examiner Signature | <i>SAG</i> | Date Considered | 5/21/02 |
|--------------------|------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 10 2002
RECEIVED
APR 16 2002

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(use as many sheets as necessary)

Sheet 16 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---|-----------------------|---|-----------------------|
|  | 189 | MASTERS, ET AL., "Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol," Clinical Chemistry, Vol. 35 (No. 6), pp. 979-984 (June 1989). | TECH CENTER 1600/2900 |
| | 190 | WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 53 (No. 5), pp. 1021-1024 (November 1981). | TECH CENTER 1600/2900 |
| | 191 | ZMUDA, ET AL., "Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men," Metabolism, Vol. 45 (No. 8), pp. 935-939 (August 1996). | TECH CENTER 1600/2900 |
| | 192 | GAIDANO, ET AL., "Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty," Clinical Chimica Acta, Vol. 100 (No. 2), pp. 91-97 (January 15, 1980). | TECH CENTER 1600/2900 |
| | 193 | Definition of Isopropyl Myristate (5103), The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition, p. 821 (1989). | TECH CENTER 1600/2900 |
| | 194 | GENNARO, ET AL., Remington's Pharmaceutical Sciences, Eighteenth Edition, pp. 1305, 1314-1315 (1990). | TECH CENTER 1600/2900 |
| | 195 | LANGTRY, ET AL., "Sildenafil - A Review of its Use in Erectile Dysfunction," Drugs, Vol. 57 (No. 6), pp. 967-989 (1999). | TECH CENTER 1600/2900 |
| | 196 | MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998). | TECH CENTER 1600/2900 |
| | 197 | FAHRNER, ET AL., "Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)," International Journal Of Sports Medicine, Vol. 19 (No. 1), pp. 12-15 (January 1998). [Abstract] | TECH CENTER 1600/2900 |
| | 198 | BARTSCH, "Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-Dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men," Maturitas, Vol. 2 (No. 2), pp. 109-118 (July 1980). [Abstract] | TECH CENTER 1600/2900 |
|  | 199 | WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," Clinical Endocrinology, Vol. 54, pp. 1-13 (2001). | TECH CENTER 1600/2900 |

Examiner
Signature

Date

Considered

5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 1 8 2002

RECEIVED
APR 1 6 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 17 of 21

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/703,753 |
| Filing Date | November 1, 2000 |
| First Named Inventor | Robert E. Dudley |
| Group Art Unit | 1617 |
| Examiner Name | S. Jiang |
| Attorney Docket Number | 01736349 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| SAJ | 200 | GOOREN, "A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate," J. Androl., Vol. 15 (No. 3), pp. 212-215 (May-June 1994). [Abstract] | |
| | 201 | MAZER, "New Clinical Applications of Transdermal Testosterone Delivery in Men and Women," J. Controlled Release, Vol. 65 (No. 1-2), pp. 303-315 (March 1, 2000). [Abstract] | |
| SAJ | 202 | ITOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level," Nippon Naibunpi Gakkai Zasshi, Vol. 67 (No. 1), pp. 23-32 (January 20, 1991). [Abstract] | |
| | 203 | Male Hormone Patch Approved, Nupharm, http://www.nupharm.com/malehorn.htm . | |
| | 204 | "SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available," International Association of Physicians in AIDS Care, http://www.iapac.org/clinimgt/compnews/sb061297.html (June-12, 1997). | |
| | 205 | "Impotence Treatments," Impotence World Association, http://www.impotenceworld.org/treatment.htm (2000). | |
| | 206 | "Andro-Gel," Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998). | |
| | 207 | "Cellegy Pharmaceuticals Market Opportunities," CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html (1999). | |
| | 208 | "Prospectus - Cellegy Pharmaceuticals, Inc.," OPPENHEIMER & CO., pp. 1-4 (21-28 (1997)). | |
| | 209 | The Testosterone Source, http://www.testosteronesource.com (1998). | |
| | 210 | BONNEY, "Hormone Replacement Therapy for Men," American Clinical Laboratory, http://iscpubs.com/pubs/acl/acl1197.html (November/December 1997). | |

Examiner
Signature

SAJ

Date
Considered

5/24/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

| | | | |
|---|----|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703,753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736349 |
| Sheet | 18 | of | 21 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 211 | Andropausal, Los Gatos Longevity Institute, http://www.antiaging.com/andropause.html (1998). | |
| | 212 | TestoCreme - A Natural Transdermal Testosterone Replacement Therapy, www.testocreme.com . | |
| SJ | 213 | WANG, ET AL., "Pharmacokinetics Of Transdermal Testosterone Gel in Hypogonadal Men," ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM. | |
| | 214 | SWERDLOFF, ETAL., "Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men," 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000). | |
| | 215 | WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000). | |
| | 216 | WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000). | |
| | 217 | "Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www. INCIID.com (August 19, 1998). | |
| SJ | 218 | RIGGS, "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel," Unimed News Release, pp. 1-2 (March 31, 1997). | |
| | 219 | Androgel 1% (testosterone gel) CII, www.Androgel.com , pp. 1-2. | |
| SJ | 220 | VERGEL, "Anabolic Steroids: A Practical Guide," CRIA Update, Vol. 7 (No. 3) (Summer 1998). | |
| | 221 | MOONEY, "Frequency of Administration - Testosterone & Nandrolone," Vol. 1 (No. 4), www.medibolics.com (Downloaded 10/8/98). | |

| | | | |
|--------------------|-----------|-----------------|--------|
| Examiner Signature | <i>SJ</i> | Date Considered | 5/2/02 |
|--------------------|-----------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 19 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|--------------------|-----------------------|---|
| | 222 | Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (December 1997). |
| | 223 | "Anabolic Steroid Boosts Weight," GMHC Treatment Issues, Vol. 10, No. 9 (September 1996). |
| | 224 | Anabolic Steroids, Project Inform Hotline Handout, www.projinf.org. (Downloaded 10/8/98). |
| | 225 | Anabolic Steroids - A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded 10/27/98). |
| | 226 | USP Drug Information - Anabolic Steroids (Systemic), Mayo Clinic, www.mayohealth.org (Downloaded 10/8/98). |
| | 227 | MOONEY, "Anabolic Steroids For AIDS Therapy: Differences Between Analogs," No. 1, www.digiweb.com. (July 1998). |
| | 228 | Testocrema - No Shots, No Pills, No Patches, www.testocrema.com (Downloaded 7/10/00). |
| | 229 | "ENDO 99: Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women," www.pslgroup.com (June 15, 1999). |
| | 230 | "Data Supports Safety of Estratest For Men," Doctor's Guide, www.pslgroup.com (March 9, 1998). |
| | 231 | "Testosterone's Role in the Female Sex Drive," USA Today News, www.usatoday.com (April 8, 1996). |
| | 232 | "Alternative to Viagra For Women?," www.mdhealthline.com (Downloaded 8/7/00). |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 20 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|-----------------------|
| SJD | 233 | "Never Too Buff," Time Europe, www.time.com, Vol. 155 (No. 16) (April 24, 2000). | TECH CENTER 1600/2900 |
| | 234 | Gefael, Graeme's Testosterone Page, www.voyager.co.nz (5/12/00). | TECH CENTER 1600/2900 |
| | 235 | Estrogel, www.netdoktor.dk/medicin/Fakta/Estrogel (Downloaded 6/26/01). | TECH CENTER 1600/2900 |
| | 236 | La Sexualite . . . , L'Androgel, Le Gel Miracle, www.aci-multimedia.net/feminin/androgel (Downloaded 5/9/01). | TECH CENTER 1600/2900 |
| | 237 | Stehli, et al., Info . . . , Info . . . , Info . . . - Androgel, www.mageos.ifrance.com/nade38/androgel (Downloaded 5/9/01). | TECH CENTER 1600/2900 |
| | 238 | CHERRIER, ET AL., "T-Gel Study: Cognitive Effects of Exogenous Testosterone Manipulation in Hypogonadal Men" (6/7/99). | TECH CENTER 1600/2900 |
| | 239 | "Bentley Pharmaceuticals Announces Research and Licensing Agreements For Intranasal Pain Management and Topical Hormone Replacement Therapy," www.bentleypharm.com (downloaded 11/17/01). | TECH CENTER 1600/2900 |
| | 240 | "Testosterone Gel May Help Men with Low Sex Drive," WRAL ONLINE, http://www.wral-tv.com/features/healthteam/T997/0814-tgel/ (August 14, 1997). | TECH CENTER 1600/2900 |
| | 241 | "Testocreme Transdermal Testosterone Is New," Preventive Medicine Clinic Of Monterey, http://www.wellnessmd.com/testo.html. | TECH CENTER 1600/2900 |
| | 242 | "SEPA Testosterone Transdermal Gel Receives Application by FDA," Doctor's Guide Global Edition, http://pslgroup.com/dg/123aa.htm (January 15, 1997). | TECH CENTER 1600/2900 |
| | 243 | Press Release - 10/21/99 -- MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone, http://www.mchm.com/press/pr24.asp (October 21, 1999). | TECH CENTER 1600/2900 |

Examiner Signature

SJD

Date

Considered

5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 16 2002

RECEIVED
APR 16 2002

| | | | |
|---|----|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/703.753 |
| | | Filing Date | November 1, 2000 |
| | | First Named Inventor | Robert E. Dudley |
| | | Group Art Unit | 1617 |
| | | Examiner Name | S. Jiang |
| | | Attorney Docket Number | 01736615 |
| Sheet | 21 | of | 21 |

| NON PATENT LITERATURE DOCUMENTS | | | TECH CENTER 1600/2900 | APR 1 6 2002 |
|---------------------------------|-----------------------|---|-----------------------|--------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | |
| | 244 | AndrosteDERM, http://www.gethuge.net/androderm1.htm . | | |
| | 245 | MANOS, "FDA Approves Gel to Treat Low Testosterone Levels," www.testocrema.com (Downloaded 5/09/01). | | |
| | 246 | "Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.INCIID.com (August 19, 1998). | | |
| SJ | 247 | LACAYO, "Are You Man Enough?," Time Europe, www.Time.com , Vol. 155, No. 16 (April 24, 2000). | | |
| | 248 | "MacroChem Accelerates Development of Top For Impotence," www.pslgroup.com (April 10, 1997). | TECH CENTER 1600/2900 | APR 6 2002 |
| SJ | 249 | BRADLEY, "Potential Expanded Indications for Androgen Treatment," The Endocrine Society, No. 166 (ENDO 2000). | | |
| | 250 | WANG, ET AL., "New Androgen Formulations," The Endocrine Society, No. 167 (ENDO 2000). | | |
| | 251 | WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," The Endocrine Society, No. 1360 (ENDO 2000). | | |
| | 252 | WITTERT, ET AL., "Androgen Deficiency in Aging Men," The Endocrine Society, No. 1626 (ENDO 2000). | | |
| SJ | 253 | BRILL, ET AL., "Single and Joint Impact of One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strength, Balance, Function and Muscle IGF-I and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover," The Endocrine Society, No. 1647 (ENDO 2000). | TECH CENTER 1600/2900 | APR 1 6 2002 |

| | | | |
|--------------------|-----------|-----------------|---------|
| Examiner Signature | <i>SJ</i> | Date Considered | 5/21/02 |
|--------------------|-----------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

RECEIVED